CLINICAL TRIALS PROFILE FOR AXICABTAGENE CILOLEUCEL
✉ Email this page to a colleague
All Clinical Trials for axicabtagene ciloleucel
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02348216 ↗ | Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma | Active, not recruiting | Kite, A Gilead Company | Phase 1/Phase 2 | 2015-01-01 | This study will be separated into 3 distinct phases designated as the Phase 1 study, Phase 2 pivotal study (Cohort 1 and Cohort 2), and Phase 2 safety management study (Cohort 3 and Cohort 4, Cohort 5 and Cohort 6). The primary objectives of this study are: - Phase 1 Study: Evaluate the safety of axicabtagene ciloleucel regimens - Phase 2 Pivotal Study; Evaluate the efficacy of axicabtagene ciloleucel - Phase 2 Safety Management Study: Assess the impact of prophylactic regimens or earlier interventions on the rate and severity of cytokine release syndrome (CRS) and neurologic toxicities |
| NCT02601313 ↗ | Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma | Active, not recruiting | Kite, A Gilead Company | Phase 2 | 2015-11-09 | The primary objective of the study is to evaluate the efficacy of brexucabtagene autoleucel (KTE-X19) in participants with relapsed/refractory mantle cell lymphoma (MCL) |
| NCT02926833 ↗ | Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Active, not recruiting | Genentech, Inc. | Phase 1/Phase 2 | 2016-09-29 | The primary objective of phase 1 is to evaluate the safety of KTE-C19 and atezolizumab combination regimens. The primary objective of phase 2 is to evaluate the efficacy of KTE-C19 and atezolizumab, as measured by complete response rate in participants with refractory diffuse large B-cell lymphoma (DLBCL). |
| NCT02926833 ↗ | Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Active, not recruiting | Kite Pharma, Inc. | Phase 1/Phase 2 | 2016-09-29 | The primary objective of phase 1 is to evaluate the safety of KTE-C19 and atezolizumab combination regimens. The primary objective of phase 2 is to evaluate the efficacy of KTE-C19 and atezolizumab, as measured by complete response rate in participants with refractory diffuse large B-cell lymphoma (DLBCL). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for axicabtagene ciloleucel
Condition Name
| Condition Name for axicabtagene ciloleucel | |
| Intervention | Trials |
| Refractory Diffuse Large B-Cell Lymphoma | 4 |
| Recurrent Diffuse Large B-Cell Lymphoma | 4 |
| Refractory High Grade B-Cell Lymphoma | 3 |
| Recurrent High Grade B-Cell Lymphoma | 3 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for axicabtagene ciloleucel
Trials by Country
Clinical Trial Progress for axicabtagene ciloleucel
Clinical Trial Phase
Clinical Trial Sponsors for axicabtagene ciloleucel
Sponsor Name
